EP0413270A2 — 4-substituted 17beta-(cyclopropylamino)androst-5-en-3beta-ol and related compounds useful as C17-20 lyase inhibitors
Assigned to Aventis Pharmaceuticals Inc · Expires 1991-02-20 · 35y expired
What this patent protects
This invention is directed to 4-substituted 17β-(cyclopropylamino)androst-5-en-3β-ol and related compounds of formula A and also to a method for using such compounds in the treatment of androgen-dependent disorders. The compounds are prepared by the hydride reduction of an approp…
USPTO Abstract
This invention is directed to 4-substituted 17β-(cyclopropylamino)androst-5-en-3β-ol and related compounds of formula A and also to a method for using such compounds in the treatment of androgen-dependent disorders. The compounds are prepared by the hydride reduction of an appropriate steroidal imine or enamine. wherein R is hydrogen or methyl; R' is hydrogen, C₁₋C₄ alkyl or cyclopropyl; and Q is wherein Z is =O, β-OH or β-OZ' wherein Z' is alkanoyl of 1-10 carbon atoms or substituted C₂₋₄ alkanoyl wherein the substituent is cyclopentane or benzene; Y' is hydrogen or halogen; and Y'' is methyl or halogen; and pharmaceutically acceptable acid addition salts thereof.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.